Pfizer heralds “paradigm shift” in hemophilia B gene therapy with FDA approval
Pfizer's groundbreaking $3.5 million gene therapy for hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine
Pfizer's groundbreaking $3.5 million gene therapy for hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine